🔥 Personalized cancer vaccines delivering impressive results at #ESMO26! @ProfGLongMIA
presents the phase III INTerpath-001 trial in resected high-risk melanoma.
Individualized neoantigen mRNA vaccine intismeran autogene + pembrolizumab vs pembrolizumab alone.
Key results:
🔹 DMFS: HR 0.62 (95% CI 0.45–0.85), p=0.002
🔹 24-month DMFS: 88.5% vs 80.2%
🔹 RFS: HR 0.58 (95% CI 0.45–0.75)
A major milestone for personalized cancer vaccines! A promising step towards truly individualized immunotherapy.
#ESMOAmbassador #ESMO26 #Melanoma #CancerVaccines #Immunotherapy
218 views · 7 likes · 1 repost · 0 replies
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.orgSource: Alfredo Addeo MD · x.com